Toripalimab-tpzi (Loqtorzi) — CPB 1049 | AETNA Coverage Update

Aetna modified CPB 1049 for toripalimab-tpzi (Loqtorzi), effective February 25, 2026. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its coverage policy for toripalimab-tpzi (Loqtorzi) under CPB 1049 Aetna system, expanding covered indications across five tumor types. The policy now governs J3263 (toripalimab-tpzi, 1 mg) for nasopharyngeal carcinoma, non-small cell lung cancer, colorectal cancer, anal carcinoma, and small bowel adenocarcinoma — all requiring precertification before administration. If your oncology billing team handles immunotherapy claims for any of these diagnoses, this policy change directly affects your authorization workflow and reimbursement exposure.

Quick-Reference Table

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Toripalimab-tpzi (Loqtorzi) — CPB 1049
Policy Code	CPB 1049
Change Type	Modified
Effective Date	February 25, 2026
Impact Level	High
Specialties Affected	Medical Oncology, Hematology/Oncology, Infusion Centers
Key Action	Verify precertification is submitted for all J3263 claims and confirm indication-specific biomarker documentation is in the record before the date of service

Aetna Toripalimab-tpzi Coverage Criteria and Medical Necessity Requirements 2026

The Aetna toripalimab-tpzi coverage policy requires precertification for every claim. Call (866) 752-7021 or fax (888) 267-3277 before treatment starts. Missing that step means a denial — full stop.

Medical necessity criteria under this coverage policy are indication-specific and tightly tied to biomarker status, prior treatment history, and combination regimen. There is no one-size-fits-all approval here. Each tumor type has its own gate.

Aetna also applies a Site of Care Utilization Management policy to toripalimab-tpzi. Before assuming office-based infusion is covered, check Aetna's Drug Infusion Site of Care policy. This is a separate prior authorization layer many billing teams miss on immunotherapy drugs.

Nasopharyngeal Carcinoma (NPC)

Aetna covers toripalimab-tpzi for NPC under two paths. First, in combination with cisplatin (J9060) and gemcitabine (J9201, J9196, or J9184) for unresectable, metastatic, or recurrent locally advanced NPC. Second, as a single agent for recurrent, unresectable, or metastatic NPC after disease progression on or following platinum-based chemotherapy.

Continuation of therapy for NPC is covered for up to 24 months total when used as first-line therapy, assuming no progression and no unacceptable toxicity. Document both of those criteria at every reauthorization request.

Non-Small Cell Lung Cancer (NSCLC)

For NSCLC, medical necessity requires absence of EGFR or ALK mutations — unless tissue is insufficient for testing. Document the biomarker testing result or the reason testing wasn't feasible. Missing that documentation is the single most common reason these claims get denied.

Aetna covers two NSCLC scenarios. First, first-line treatment in combination with platinum-doublet chemotherapy, followed by single-agent maintenance. Second, neoadjuvant treatment combined with platinum-doublet chemotherapy, continuing as single-agent adjuvant therapy after surgery. These are distinct clinical pathways — make sure the claim narrative and prior auth request match the actual regimen.

Colorectal Cancer and Appendiceal Adenocarcinoma

Coverage here requires biomarker-confirmed MSI-H, dMMR, or POLE/POLD1 mutation with ultra-hypermutated phenotype. Toripalimab-tpzi is covered as a single agent for unresectable, medically inoperable, advanced, or metastatic disease. Appendiceal adenocarcinoma is explicitly included.

This is where ICD-10 specificity matters. Aetna's policy lists C18.0–C18.9, C19, and C20 for colon and rectal malignancies. Map the diagnosis to the most specific code available and attach biomarker documentation to the prior auth.

Anal Carcinoma

Toripalimab-tpzi is covered as a single agent for subsequent treatment of metastatic anal carcinoma, provided the member has not received prior immunotherapy. ICD-10 codes C21.0 through C21.8 apply here.

No prior immunotherapy — that's the hard line. If the patient received any PD-1 or PD-L1 inhibitor previously, Aetna excludes coverage. Run that history before submitting the prior auth.

Small Bowel Adenocarcinoma

Same biomarker requirement as colorectal: MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated phenotype. Coverage is for locally unresectable, medically inoperable, advanced, or metastatic small bowel adenocarcinoma as a single agent. ICD-10 codes C17.0 through C17.9 apply.

Aetna Toripalimab-tpzi Exclusions and Non-Covered Indications

The hard exclusion is simple: any member who progressed while on a PD-1 or PD-L1 inhibitor is not eligible for Loqtorzi coverage under this policy. Period.

This is a blanket exclusion — it applies across all indications. It doesn't matter which tumor type or which combination regimen is proposed. Prior checkpoint inhibitor failure equals denial.

Aetna also designates all indications not listed in the policy as experimental, investigational, or unproven. If a physician wants to use toripalimab-tpzi for an off-label indication not covered in CPB 1049, expect a denial. The policy does not leave room for clinical judgment on unlisted uses.